Abstract: Holding mechanisms for an electromagnetic core, assemblies thereof, and methods of manufacturing same are disclosed, such as for electromagnetic cores having a predetermined number of limbs. According to some embodiments, the holding mechanism may include a hub having an axis, wherein the hub comprises a plurality of apertures corresponding to the predetermined number of limbs of the electromagnetic core, such as an aperture in the hub per limb of the electromagnetic core. Each of the apertures may be configured to receive an end portion of a respective limb radially around the axis. Further, the axis of the hub may be coincident with the central axis of the electromagnetic core when the predetermined number of limbs of the electromagnetic core are received in the plurality of apertures. In one implementation, the holding mechanism comprises a plurality of jaws corresponding to the predetermined number of limbs of the electromagnetic core.

Abstract: An electrical power control apparatus, including: a magnetic core having a plurality of phase limbs for respective phases of electric power, each of the phase limbs being interconnected to the other phase limbs at respective ends of the limb; primary windings around the respective phase limbs to receive input electrical energy in the form of input signals for the respective electrical phases and generate corresponding magnetic fluxes in the phase limbs; secondary windings around the respective phase limbs to generate output electrical energy in the form of output signals for respective electrical phases from magnetic fluxes in the phase limbs; and control windings around respective portions of the magnetic core to receive control signals for respective electrical phases to modify the magnetic fluxes in the respective phase limbs in order to modify the output signals generated from the secondary windings so that the output signals have one or more electrical attributes that satisfy respective predetermined cri

Abstract: Provided herein are methods for treating cancer, such as breast cancer, by administering an inhibitor of NMES1. Further provided herein are NMES1 monoclonal antibodies which may be used to detect or treat cancer.

Abstract: The current disclosure describes therapeutic methods for treating cancer by inhibition of G protein-coupled receptor 132 (GPR132) in the tumor microenvironment. Aspects of the disclosure relate to a method for reducing and/or inhibiting cancer cell proliferation or tumor growth in a subject having cancerous cells or tumor growth, the method comprising administering an effective amount of an agent that inhibits GPR132 to the subject.

Abstract: The use of miR-34a and agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases.

Abstract: The use of orexin 1 receptor antagonists and/or orexin 2 receptor agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases.

Abstract: The disclosure describes the use of anti-IGFBP1 antibodies to inhibit the bone loss-inducing properties of FGF21. This can be applied in the context of FGF21 treatment for obesity and/or diabetes, or in menopause-induced bone loss, such as osteoporosis.

Abstract: The use of miR-34a and agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases.